| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | NEUTRAL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 2.47▲ | 2.45▲ | 2.45▲ | 2.51▼ | 3.75▼ |
| MA10 | 2.47▲ | 2.46▲ | 2.46▲ | 2.85▼ | 3.04▼ |
| MA20 | 2.46▲ | 2.46▲ | 2.48▼ | 3.68▼ | 2.78▼ |
| MA50 | 2.47▲ | 2.51▼ | 2.68▼ | 3.24▼ | 3.34▼ |
| MA100 | 2.50▼ | 2.74▼ | 3.33▼ | 3.10▼ | 109.09▼ |
| MA200 | 2.53▼ | 3.53▼ | 3.75▼ | 3.76▼ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.005▲ | 0.005▲ | 0.017▲ | -0.228▼ | 0.706▲ |
| RSI | 53.774▲ | 49.634▼ | 43.398▼ | 43.984▼ | 42.053▼ |
| STOCH | 94.639▲ | 35.000 | 40.625 | 6.748▼ | 22.968 |
| WILL %R | 0.000▲ | -41.667 | -56.250 | -97.153▼ | -86.515▼ |
| CCI | 82.353 | 29.209 | 19.336 | -86.652 | -26.894 |
|
Tuesday, April 28, 2026 01:38 PM
Filing seeks to extend EL-22 myostatin-engineered probiotic platform into pharmaceutical applications for muscle preservation in patients on GLP-1 receptor agonists and across multiple muscle-wasting ...
|
|
Tuesday, April 28, 2026 04:37 AM
NorthStrive Biosciences Inc. (“NorthStrive” or the “Company”), a wholly owned subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB) (“PMGC”), today announced the filing of a new U.S. patent application ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 30/04/26 | 2.46 | 2.52 | 2.40 | 2.46 | 237,560 |
| 29/04/26 | 2.55 | 2.555 | 2.41 | 2.53 | 356,552 |
| 28/04/26 | 2.38 | 2.575 | 2.38 | 2.54 | 441,717 |
| 27/04/26 | 2.41 | 2.7397 | 2.4001 | 2.54 | 522,402 |
| 24/04/26 | 2.81 | 2.85 | 2.45 | 2.49 | 813,261 |
| 23/04/26 | 3.14 | 3.20 | 2.77 | 2.94 | 5,504,256 |
| 22/04/26 | 3.06 | 3.15 | 2.85 | 3.11 | 937,320 |
| 21/04/26 | 3.30 | 3.3487 | 3.1501 | 3.29 | 1,363,982 |
| 20/04/26 | 3.30 | 3.57 | 3.26 | 3.32 | 1,044,829 |
| 17/04/26 | 3.95 | 4.17 | 3.25 | 3.28 | 10,475,294 |
|
|
||||
|
|
||||
|
|